ArticlePediatric rheumatology online journal2021
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.
Article in Pediatric rheumatology online journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.Pediatric rheumatology online journal · 2026Article
- Advances in tumor necrosis factor-α inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis.Frontiers in immunology · 2026Review
- To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF.Journal of translational autoimmunity · 2024Review
- Efficacy of golimumab in patients with refractory non-infectious panuveitis.Scientific reports · 2024Article
- Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients.Paediatric drugs · 2024Review
- A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.Proceedings (Baylor University. Medical Center) · 2024Article
- Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations.Life (Basel, Switzerland) · 2023Review
- An Overview of Pediatric Uveitis.Turkish archives of pediatrics · 2023Article
- Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.Children (Basel, Switzerland) · 2023Review
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Biologic therapies for juvenile idiopathic arthritis-associated uveitis.Frontiers in ophthalmology · 2022Review
- Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database.Therapeutics and clinical risk management · 2022Article
- Juvenile idiopathic arthritis and associated uveitis: A review of pathogenesis, diagnosis, and management.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- Subcutaneous golimumab in the treatment of Juvenile idiopathic arthritis-associated anterior uveitis after failing other tumor necrosis factor alpha inhibitors.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA).
methodsRetrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uveitis-related data, including intraocular inflammation, best-corrected visual acuity, corticosteroid-sparing potential, and ocular complications were evaluated at start of GLM treatment, at 1 month and 3 months, and every 3 months thereafter during GLM administration. We further investigated the association of response to GLM with primary and secondary failure of ADA treatment.
resultsTen patients were studied, all female (17 affected eyes, mean age 14.3 + 6.7 yrs., mean follow-up 25.2 + 21.7 mos). Two patients were switched to GLM because of primary non-response to ADA. Eight were switched because of loss of response (LOR). In 5 of the latter LOR was associated with neutralizing anti-ADA-antibodies. Response to GLM was observed in all 8 patients with LOR, while the 2 patients with primary non-response to ADA also did not respond to GLM. Three of the 8 responders experienced LOR. At the end of follow-up 4 of the 5 remaining responders had achieved complete response. One had achieved partial response.
conclusionGLM is an efficacious therapeutic option in patients who experience LOR to ADA. Our data indicate that patients without primary response to ADA should be rather switched to a biologic agent with a different mode of action instead of further blocking the TNF-alpha pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.